Anti-Hu CD33 PerCP

*Hernández-Caselles T, Martínez-Esparza M, Pérez-Oliva AB, Quintanilla-Cecconi AM, García-Alonso A, Alvarez-López DM, García-Peñ arrubia P: A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol. 2006 Jan;79 (1) :46-58., URL: http://www.ncbi.nlm.nih.gov/pubmed/16380601 , *Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P: Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005 Feb 1;105 (3) :1256-64., URL: http://www.ncbi.nlm.nih.gov/pubmed/15388576 , *Schenk M, Bouchon A, Birrer S, Colonna M, Mueller C: Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine. J Immunol. 2005 Jan 1;174 (1) :517-24., URL: http://www.ncbi.nlm.nih.gov/pubmed/15611278 , *Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, Lombardi M, Galiuto L, Liuzzo G, Andreotti F, Lanza GA, Contemi AM, Leone G, Crea F: Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005 Jun;26 (12) :1196-204., URL: https://www.ncbi.nlm.nih.gov/pubmed/15734770, *Hernández-López C, Varas A, Sacedón R, Jiménez E, Muñoz JJ, Zapata AG, Vicente A: Stromal cell-derived factor 1/CXCR4 signaling is critical for early human T-cell development. Blood. 2002 Jan 15;99 (2) :546-54., URL: https://www.ncbi.nlm.nih.gov/pubmed/11781237, *Vitale C, Romagnani C, Puccetti A, Olive D, Costello R, Chiossone L, Pitto A, Bacigalupo A, Moretta L, Mingari MC: Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci U S A. 2001 May 8;98 (10) :5764-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/11320212, *Shin YK, Choi EY, Kim SH, Chung J, Chung DH, Park WS, Jung KC, Kim HS, Park S, Kim HJ, Park MH, Min CK, Kim CC, Park SH: Expression of leukemia-associated antigen, JL1, in bone marrow and thymus. Am J Pathol. 2001 Apr;158 (4) :1473-80., URL: https://www.ncbi.nlm.nih.gov/pubmed/11290565, *Bradstock KF, Kirk J, Grimsley PG, Kabral A, Hughes WG: Unusual immunophenotypes in acute leukaemias: incidence and clinical correlations. Br J Haematol. 1989 Aug;72 (4) :512-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/2673329, *Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Zowtyj H, Zola H: Further characterization of human myeloid antigens (gp160,95; gp150; gp67) : investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies belonging to CD-11b, CD-13 and CD-33. Br J Haematol. 1988 Jun;69 (2) :163-71., URL: https://www.ncbi.nlm.nih.gov/pubmed/2455535, *Favaloro EJ, Bradstock KF, Kabral A, Grimsley P, Berndt MC: Characterization of monoclonal antibodies to the human myeloid-differentiation antigen, 'gp67' (CD-33) . Dis Markers. 1987 Dec;5 (4) :215-25. , URL: https://www.ncbi.nlm.nih.gov/pubmed/3502990

*Walter RB, Häusermann P, Raden BW, Teckchandani AM, Kamikura DM, Bernstein ID, Cooper JA: Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface Receptor. Traffic. 2007 Dec 18, URL: https://www.ncbi.nlm.nih.gov/pubmed/18062779?ordin, *Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA: CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood. 2007 Feb 1;109 (3) :1061-8., URL: https://www.ncbi.nlm.nih.gov/pubmed/17008544?ordin, *Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML: The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol. 1999 Nov;29 (11) :3440-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/10556798?ordin